Peter Devine

Peter Devine serves as the Chief Executive Officer at Uniseed, a venture fund associated with leading Australian universities and the CSIRO, achieving significant capital returns through various commercial deals. In parallel, Peter holds multiple leadership roles including Chair and Non-Executive Director positions at Kinoxis Therapeutics, PERKii Enhanced Probiotics, and ProGel Microgel Technology, among others. A background in drug development is highlighted by past involvement with Spinifex Pharmaceuticals, which was acquired by Novartis for US$700 million. Peter's academic credentials include an MBA from AGSM @ UNSW and a PhD from The University of Queensland in Gynaecological Oncology.